Court Victory and Fresh Funding Propel Growth at Liquidia Corporation
Located in North Carolina, Liquidia Corporation (NASDAQ:LQDA) develops and commercializes treatments for rare cardiopulmonary diseases.
Liquidia Corp (LQDA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Caligan Partners David Johnson | 8,118,892 | $101,161,394 | +1% | 19.45% |
| 2. | Farallon Capital Thomas Steyer | 4,238,762 | $52,814,975 | +7% | 0.23% |
| 3. | Findell Capital Management Brian Finn | 3,000,000 | $37,380,000 | +4% | 18.2% |
| 4. | Opaleye Management James A. Silverman | 2,475,000 | $30,838,500 | +10% | 6.24% |
| 5. | Deerfield Management James E. Flynn | 1,616,778 | $20,145,054 | 0.37% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.90 | 337,078 | $2,999,994.20 | 816,311 | 2024-09-12 | Filing | |
| $9.51 | 150,000 | $1,426,500.00 | 6,994,997 | 2024-08-30 | Filing | |
| $7.16 | 139,665 | $1,000,001.40 | 640,805 | 2023-12-14 | Filing | |
| $7.16 | 279,330 | $2,000,002.80 | 279,330 | 2023-12-14 | Filing | |
| $7.16 | 1,117,318 | $7,999,996.88 | 11,280,945 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.17 | 5,000 | $135,850.00 | 33,755 | 2025-08-19 | Filing | |
| $26.18 | 20,000 | $523,674.00 | 356,412 | 2025-08-15 | Filing | |
| $20.00 | 30,000 | $600,132.00 | 376,412 | 2025-08-05 | Filing | |
| $19.54 | 454 | $8,871.16 | 193,180 | 2025-07-28 | Filing | |
| $19.54 | 1,063 | $20,771.02 | 186,105 | 2025-07-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,892,135 | $60,956,003 | 0% | |
| 2. | 3,593,558 | $44,775,732 | 0% | |
| 3. | 2,417,005 | $30,115,882 | 0% | |
| 4. | 1,830,701 | $22,810,534 | 0% | |
| 5. | 1,631,948 | $20,350,392 | 0.01% |
News See All
11 Best Short Squeeze Stocks to Buy Now
The latest U.S. tariff wave has created a suitable environment where short squeeze investments will thrive.
Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge
Liquidia rallied for a third straight day on Tuesday, ending 13.68 percent higher at $24.10 as investor sentiment was bolstered by the higher prescription rate for its newly approved pulmonary hypertension...
Liquidia Corporation (NASDAQ:LQDA) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome, everyone, to the Liquidia Corporation Second Quarter 2025 Financial Results and Corporate Update Conference Call.
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus
Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling
Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
BTIG Raises Liquidia Price Target Following YUTREPIA Approval
This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute
Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S.
Billionaire Hedge Funds
